{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:24:52Z","timestamp":1788888292071,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["12\/201\/02"],"award-info":[{"award-number":["12\/201\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2801-6","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T11:33:46Z","timestamp":1533036826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8078-409X","authenticated-orcid":false,"given":"Nefyn H.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia","family":"Goulden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyfrig A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eifiona","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine E.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Carnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Sparkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kika","family":"Konstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaro","family":"Karppinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Genevay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"2801_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jama.1992.03490060092030","volume":"268","author":"R Deyo","year":"1992","unstructured":"Deyo R, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268:760\u20135.","journal-title":"JAMA"},{"key":"2801_CR2","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1097\/BRS.0b013e318183a4a2","volume":"33","author":"K Konstantinou","year":"2008","unstructured":"Konstantinou K, Dunn KM. Sciatica: review of epidemiological studies and prevalence estimates. Spine. 2008;33:2464\u201372.","journal-title":"Spine"},{"key":"2801_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/00007632-199309010-00006","volume":"18","author":"H Weber","year":"1993","unstructured":"Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine. 1993;18:1433\u20138.","journal-title":"Spine"},{"key":"2801_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/00007632-199210000-00013","volume":"17","author":"K Bush","year":"1992","unstructured":"Bush K, Cowan N, Katz DE, Gishen P. The natural history of sciatica associated with disc pathology; a prospective study with clinical and independent radiological follow-up. Spine. 1992;17:1205\u201312.","journal-title":"Spine"},{"key":"2801_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0895-4356(03)00257-9","volume":"57","author":"F Tubach","year":"2004","unstructured":"Tubach F, Beaut\u00e9 J, Leclerc A. Natural history and prognostic indicators of sciatica. J Clin Epidemiol. 2004;57:174\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2801_CR6","unstructured":"National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE Guideline. 2016. nice.org.uk\/guidance\/ng59 . Accessed 3 Oct 2017."},{"key":"2801_CR7","unstructured":"UK Spine Societies Board. National Backpain Pathway. 2017. http:\/\/www.ukssb.com\/pages\/Improving-Spinal-Care-Project\/National-Backpain-Pathway.html . Accessed 3 Oct 2017."},{"key":"2801_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1136\/bmj.39223.428495.BE","volume":"334","author":"B Koes","year":"2007","unstructured":"Koes B, van Tulder MW, Peul WC. Diagnosis and treatment of sciatica. BMJ. 2007;334:1313\u20137.","journal-title":"BMJ"},{"key":"2801_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00586-007-0367-1","volume":"16","author":"P Luijsterburg","year":"2007","unstructured":"Luijsterburg P, Verhagen AP, Ostelo RW, van Os TA, Peul WC, Koes BW. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Eur Spine J. 2007;16:881\u201399.","journal-title":"Eur Spine J"},{"key":"2801_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1056\/NEJM193408022110506","volume":"211","author":"W Mixer","year":"1934","unstructured":"Mixer W, Barr J. Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med. 1934;211:210\u20135.","journal-title":"N Engl J Med"},{"key":"2801_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0049-0172(98)80029-2","volume":"28","author":"P Goupille","year":"1998","unstructured":"Goupille P, Jayson M, Valat JP, Freemont AJ. The role of inflammation in disc herniation associated radiculopathy. Semin Arthritis Rheum. 1998;28:60\u201371.","journal-title":"Semin Arthritis Rheum"},{"key":"2801_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00007632-198401000-00004","volume":"9","author":"B Revdivik","year":"1984","unstructured":"Revdivik B, Brown M, Lundborg G. Pathoanatomy and pathophysiology of nerve root compression. Spine. 1984;9:7\u201315.","journal-title":"Spine"},{"key":"2801_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/rheumatology\/keh013","volume":"43","author":"RG Cooper","year":"2004","unstructured":"Cooper RG, Freemont AJ. TNF-\u03b1 blockade for herniated intervertebral disc-induced sciatica: a way forward at last? Rheumatol. 2004;43:119\u201321.","journal-title":"Rheumatol"},{"key":"2801_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.spinee.2013.08.049","volume":"15","author":"R Lewis","year":"2015","unstructured":"Lewis R, Williams NH, Sutton A, Burton K, Matar HE, Hendry M, et al. Comparative clinical effectiveness of management strategies for sciatica: systematic review and network meta-analyses. Spine J. 2015;15:1461\u201377.","journal-title":"Spine J"},{"key":"2801_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1177\/1060028017722008","volume":"51","author":"JR Guo","year":"2017","unstructured":"Guo JR, Jin XJ, Shen HC, Wang H, Zhou X, Liu XQ, Zhu NN. A comparison of the efficacy and tolerability of the treatments for sciatica: a network meta-analysis. Ann Pharmacother. 2017;51:1041\u201352.","journal-title":"Ann Pharmacother"},{"key":"2801_CR16","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00586-013-2739-z","volume":"22","author":"N Williams","year":"2013","unstructured":"Williams N, Lewis R, Din NU, Matar HE, Fitzsimmons D, Phillips CJ, et al. A systematic review and meta-analysis of biological treatments targeting tumour necrosis factor \u03b1 for sciatica. Eur Spine J. 2013;22:1921\u201335.","journal-title":"Eur Spine J"},{"key":"2801_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0304-3959(94)00272-G","volume":"62","author":"MW van Tulder","year":"1995","unstructured":"van Tulder MW, Koes B, Bouter LM. A cost of illness study of back pain in the Netherlands. Pain. 1995;62:233\u201340.","journal-title":"Pain"},{"key":"2801_CR18","unstructured":"NHS England. What is a biosimilar medicine? 2015. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2015\/09\/biosimilar-guide.pdf . Accessed 8 Nov 2017."},{"key":"2801_CR19","unstructured":"European Medicines Agency. 04\/04\/2012 Humira - EMEA\/H\/C\/00481 -II\/0082. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000481\/human_med_000822.jsp&mid=WC0b01ac058001d124&murl=menus\/medicines\/medicines.jsp . Accessed 7 Aug 2014."},{"key":"2801_CR20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/sim.4175","volume":"30","author":"D Russell","year":"2011","unstructured":"Russell D, Hoare ZSJ, Whitaker R, Whitaker CJ, Russell IT. Generalized method for adaptive randomization in clinical trials. Stat Med. 2011;30:922\u201334.","journal-title":"Stat Med"},{"key":"2801_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/BMR-2005-183-401","volume":"18","author":"A Bakhtiary","year":"2005","unstructured":"Bakhtiary A, Safavi-Farokhi Z, Rezasoltani A. Lumbar stabilizing exercises improve activities of daily living in patients with lumbar disc herniation. J Back Musculoskelet Rehabil. 2005;18:55\u201360.","journal-title":"J Back Musculoskelet Rehabil"},{"key":"2801_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/BRS.0b013e31821ace7f","volume":"37","author":"H Albert","year":"2012","unstructured":"Albert H, Manniche C. The efficacy of systematic active conservative treatment for patients with severe sciatica: a single-blinded randomized clinical controlled trial. Spine. 2012;37:531\u201342.","journal-title":"Spine"},{"key":"2801_CR23","first-page":"271","volume":"66","author":"J Fairbank","year":"1980","unstructured":"Fairbank J, Couper J, Davies JB, O\u2019Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980;66:271\u20133.","journal-title":"Physiotherapy"},{"key":"2801_CR24","first-page":"199","volume":"16","author":"EuroQol Group","year":"1999","unstructured":"EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy. 1999;16:199\u2013208.","journal-title":"Health Policy"},{"key":"2801_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00007632-198303000-00004","volume":"8","author":"M Roland","year":"1983","unstructured":"Roland M, Morris RA. Study of the natural history of back pain: part I: development of a reliable and sensitive measure of disability in low-back pain. Spine. 1983;8:141\u20134.","journal-title":"Spine"},{"key":"2801_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00701-010-0679-5","volume":"152","author":"M Kim","year":"2010","unstructured":"Kim M, Guilfoyle R, Seeley HM, Laing RJC. A modified Roland-Morris disability scale for the assessment of sciatica. Acta Neurochir. 2010;152:1549\u201353.","journal-title":"Acta Neurochir"},{"key":"2801_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00586-009-1042-5","volume":"19","author":"L Gr\u00f8vle","year":"2010","unstructured":"Gr\u00f8vle L, Haugen AJ, Keller A, Natvig B, Brox JI, Grotle M. The bothersomeness of sciatica: patients\u2019 self-report of paresthesia, weakness and leg pain. Eur Spine J. 2010;19:263\u20139.","journal-title":"Eur Spine J"},{"key":"2801_CR28","doi-asserted-by":"publisher","first-page":"E455","DOI":"10.1097\/01.brs.0000174274.38485.ee","volume":"30","author":"R Lacey","year":"2005","unstructured":"Lacey R, Lewis M, Jordan K, Jinks C, Sim J. Pain location using a pain manikin. Spine. 2005;30:E455\u20138.","journal-title":"Spine"},{"key":"2801_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"A Zigmond","year":"1983","unstructured":"Zigmond A, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"2801_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1524-4733.2010.00788.x","volume":"13","author":"C Ridyard","year":"2010","unstructured":"Ridyard C, Hughes DA. Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK health technology assessment program. Value Health. 2010;13:867\u201372.","journal-title":"Value Health"},{"key":"2801_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40258-013-0022-4","volume":"11","author":"J Thorn","year":"2013","unstructured":"Thorn J, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, et al. Resource-use measurement based on patient recall: issues and challenges for economic evaluation. Appl Health Econ Health Pol. 2013;11:155\u201361.","journal-title":"Appl Health Econ Health Pol"},{"key":"2801_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/art.23563","volume":"59","author":"J Hill","year":"2008","unstructured":"Hill J, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. Arthritis Rheum. 2008;59:632\u20134.","journal-title":"Arthritis Rheum"},{"key":"2801_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pain.2005.12.012","volume":"121","author":"K Dunn","year":"2006","unstructured":"Dunn K, Croft PR. The importance of symptom duration in determining prognosis. Pain. 2006;121:126\u201332.","journal-title":"Pain"},{"key":"2801_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejpain.2005.12.008","volume":"11","author":"M Nicholas","year":"2007","unstructured":"Nicholas M. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain. 2007;11:153\u201363.","journal-title":"Eur J Pain"},{"key":"2801_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0304-3959(94)00279-N","volume":"62","author":"J Vlaeyen","year":"1995","unstructured":"Vlaeyen J, Kole-Snijders AMJ, Boren RGB, van Eek H. Fear of movement\/(re)injury in chronic low back pain and its relation to behavioural performance. Pain. 1995;62:363\u201372.","journal-title":"Pain"},{"key":"2801_CR36","unstructured":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use - Good Clinical Practice. 1996. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf . Accessed 8 Nov 2017."},{"key":"2801_CR37","unstructured":"Department of Health. Attributing the costs of health and social care research and development. 2015. https:\/\/www.gov.uk\/government\/publications\/guidance-on-attributing-the-costs-of-health-and-social-care-research . Accessed 8 Nov 2017."},{"key":"2801_CR38","unstructured":"Public Health England. Tuberculosis strategy for England 2015-2020. NHS England 2015. https:\/\/www.england.nhs.uk\/tb-strategy . Accessed 8 Nov 2017."},{"key":"2801_CR39","unstructured":"Lloyd Johnson. Health experts call for action as tower hamlets ranked among worst London areas for TB. East London Lines Health 2015. http:\/\/www.eastlondonlines.co.uk\/2015\/10\/tower-hamlets-among-worst-london-areas-for-tb\/ . Accessed 8 Nov 2017."},{"key":"2801_CR40","unstructured":"Association of Research Managers and Administrators. Brunswick Agreements. https:\/\/arma.ac.uk\/updated-brunswick-agreements\/ . Accessed 12 Dec 2016."},{"key":"2801_CR41","unstructured":"National Institute of Health Research. Collaborations for early phase translational research. https:\/\/www.nihr.ac.uk\/life-sciences-industry\/access-to-expertise-and-collaborations\/collaborations-for-early-phase-translational-research\/ . Accessed 8 Nov 2017."},{"key":"2801_CR42","unstructured":"NHS England. Excess treatment costs. 2015. https:\/\/www.england.nhs.uk\/commissioning\/research\/etc\/ . Accessed 9 Nov 2017."},{"key":"2801_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12891-015-0787-8","volume":"16","author":"K Konstantinou","year":"2015","unstructured":"Konstantinou K, Dunn KM, Ogollah R, Vogel S, Hay EM, ATLAS study research team. Characteristics of patients with low back and leg pain seeking treatment in primary care: baseline results from the ATLAS cohort study. BMC Musculoskelet Disord. 2015;16:332.","journal-title":"BMC Musculoskelet Disord"},{"key":"2801_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12891-017-1513-5","volume":"18","author":"NE Foster","year":"2017","unstructured":"Foster NE, Konstantinou K, Lewis M, Ogollah R, Dunn KM, van der Windt D, et al. The clinical and cost-effectiveness of stratified care for patients with sciatica: the SCOPiC randomised controlled trial protocol (ISRCTN75449581). BMC Musculoskelet Disord. 2017;18:172.","journal-title":"BMC Musculoskelet Disord"},{"key":"2801_CR45","unstructured":"National Institute of Health Research. Push the pace. https:\/\/www.nihr.ac.uk\/about-us\/how-we-are-managed\/boards-and-panels\/push-the-pace.htm . Accessed 9 Nov 2017."},{"key":"2801_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/BSD.0b013e31819afdc4","volume":"23","author":"T Okoro","year":"2010","unstructured":"Okoro T, Tafazl S, Longworth S, Sell PJ. Tumour necrosis factor \u03b1-blocking agent (etanercept); a triple blind randomized controlled trial of its use in treatment of sciatica. J Spinal Disord Tech. 2010;23:74\u20137.","journal-title":"J Spinal Disord Tech"},{"issue":"3","key":"2801_CR47","doi-asserted-by":"publisher","first-page":"BJGP-2016-0872","DOI":"10.3399\/bjgpopen17X101085","volume":"1","author":"WH van der Gaag","year":"2017","unstructured":"van der Gaag WH, van den Berg R, Koes BW, Bohnen AM, Hazen LMG, Peul WC, et al. Discontinuation of a randomised controlled trial in general practice due to unsuccessful patient recruitment. BJGP Open. 2017;1(3):BJGP-2016-0872.","journal-title":"BJGP Open"},{"key":"2801_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1745-6215-14-166","volume":"14","author":"BGO Sully","year":"2013","unstructured":"Sully BGO, Julious SA, Nicholl J. A re-investigation of recruitment to randomised, controlled, multi-centre trials: a review of trials funded by two UK funding agencies. Trials. 2013;14:166.","journal-title":"Trials"},{"key":"2801_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2288-6-34","volume":"6","author":"JM Watson","year":"2006","unstructured":"Watson JM, Torgerson DJ. Increasing recruitment to trials: a review of randomised controlled trials. BMC Med Res Methodol. 2006;6:34.","journal-title":"BMC Med Res Methodol"},{"key":"2801_CR50","doi-asserted-by":"publisher","first-page":"e002360","DOI":"10.1136\/bmjopen-2012-002360","volume":"3","author":"S Treweek","year":"2013","unstructured":"Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrom M, Johansen M, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open. 2013;3:e002360.","journal-title":"BMJ Open"},{"key":"2801_CR51","doi-asserted-by":"publisher","first-page":"e000496","DOI":"10.1136\/bmjopen-2011-000496","volume":"2","author":"P Fletcher","year":"2012","unstructured":"Fletcher P, Gheorgle A, Moore D, Wilson S, Damery S. Improving the recruitment activity in randomised controlled trials: a systematic review. BMJ Open. 2012;2:e000496.","journal-title":"BMJ Open"},{"key":"2801_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","volume":"17","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet recruitment intervention (QRI). Trials. 2016;17:283.","journal-title":"Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2801-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2801-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2801-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:17:21Z","timestamp":1604715441000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2801-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2801"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2801-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"4 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Wales REC 3 granted approval on 27 May 2015 (15\/WA\/105), and clinical trial authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) was granted on 15 April 2015 (21996\/0002\/001-0001). Informed consent was obtained from all participants in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NHW declares membership of the Health Technology Assessment (HTA) Primary Care, Community and Preventative Interventions Panel. DAH reports other grants from the National Institute for Health Research (NIHR) during the conduct of the study and membership of the HTA Clinical Trials Board from 2010 to 2016, the HTA Funding Teleconference from 2015 to 2016 and the Pharmaceuticals Panel from 2008 to 2012. EW reports receipt of other grants from NIHR during the conduct of the study. NEF declares membership of the HTA Primary Care, Community and Preventative Interventions Panel. DAW reports receipt of grants from Pfizer Ltd. and personal fees from Novartis Pharmaceuticals UK Ltd. and Pfizer Ltd. outside the submitted work. KK reports other grants from NIHR during the conduct of the study. JK reports receipt of personal fees from lectures (Pfizer Ltd., Merck & Co., Inc., and ORION Pharma GmbH), personal fees from a scientific advisory board (Axsome Therapeutics Inc.) and personal fees from stocks (ORION Pharma GmbH) outside the submitted work. SG reports receipt of grants from AbbVie Inc., Merck & Co., Inc., Pfizer Ltd., University Hospitals of Geneva, the Rheumasearch Foundation, Fondation de bienfaisance, Eugenio Litta and Centre de Recherches outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"408"}}